PER-056-02Completed未知
CLINICAL PHASE II STUDY OF IROFULVEN IN COMBINATION WITH IRINOTECAN IN PATIENTS WITH ADVANCED SOLID TUMORS GASTROINTESTINALES
MGI PHARMA, INC.,0 sites0 target enrollmentStarted: August 23, 2002Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •Patients with advanced gastrointestinal solid tumors without standard chemotherapy treatment or progressed to standard chemotherapy.
- •Disease measurable / evaluable by the RECIST criteria.
- •Age 18 years.
- •ECOG Performance Status (PS): 0-1
- •Life expectancy> 3 months.
Exclusion Criteria
- •Previous chemotherapy with topoisomerase I inhibitors
- •Previous intestinal obstruction / subostruction not completely resolved or chronic diarrhea, chronic enteropathy, extensive intestinal resection (> hemicolectomy).
- •Patients with radiant treatment in more than 35% of the bone marrow after admission to the study.
- •Presence of any serious concomitant systemic disorder incompatible with the study.
- •Presence of any disorder of the central nervous or psychiatric system that may hinder the participation of the patient in the study.
Investigators
Similar Trials
Active, not recruiting
Phase 1
Phase II study of Irofulven in AR-targeted and Docetaxel-Pretreated Metastatic Castration-Resistant Prostate Cancer Patients, who have a Drug Response Predictor (DRP™) indicating a high likelihood of response to IrofulveEUCTR2017-003549-72-DKOncology Venture Aps27
Completed
Phase 2
Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal CancerPrimary Peritoneal Cavity CancerRecurrent Ovarian Epithelial CancerNCT00053365National Cancer Institute (NCI)61
Completed
Phase 2
Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)Metastatic Castration-Resistant Prostate Cancer PatientsNCT03643107Allarity Therapeutics15
Completed
Phase 2
Study of Irofulven in Patients With Hormone-refractory Prostate CancerProstate CancerNCT00124566Eisai Inc.135
Active, not recruiting
Phase 1
Evaluate the safety and the efficacy of Vemurafenib/PEG-interferon in melanoma patientsEvaluate the safety and the efficacy of Vemurafenib/PEG-interferon combination and the IFNAR1 upregulation lead by this treatment in advanced melanoma patients harboring the V600BRAF mutationMedDRA version: 14.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864EUCTR2013-003730-33-ITFondazione Melanoma ONLUS48